{
    "nct_id": "NCT03281369",
    "official_title": "A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)",
    "inclusion_criteria": "Gastric Cancer Cohorts Inclusion Criteria:\n\n* Age >/= 18 years;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;\n* Life expectancy >/= 3 months, as determined by the investigator;\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma of gastric or gastroesophageal junction; (for the 1L Gastric Cancer Cohort: no prior systemic therapy for the locally advanced or metastatic disease; for the 2L Gastric Cancer Cohort: disease progression during or following a first-line platinum-containing or fluoropyrimidine-containing chemotherapy regimen);\n* Availability of a representative tumor specimen that is suitable for determination of PD-L1 and TIGIT levels by IHC and/or additional biomarker status by means of retrospective central testing;\n* Only for the 1L Gastric Cancer Cohort: human epidermal growth factor receptor 2 (HER2)-negative tumors;\n* Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1);\n* Adequate hematologic and end organ function based on laboratory results obtained within 14 days prior to initiation of study treatment;\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm;\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm.\n\nEsophageal Cancer Cohort Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of squamous cell carcinoma or adenocarcinoma of the esophagus in locally advanced or metastatic disease;\n* No prior systemic treatment for esophageal cancer, with the following exception:\n\nFor patients treated with chemotherapy in the locally advanced setting: occurrence of metastasis after 6 months from the last dose of chemotherapy;\n\n* For patients with adenocarcinoma: absence of HER2 expression;\n* Life expectancy >/=3 months as determined by the investigator;\n* Measurable disease per RECIST v1.1;\n* Adequate hematologic and end-organ function;\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs;\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm;\n* ECOG Performance Status of 0, 1, or 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Exclusion criteria for the 2L Gastric Cancer Cohort:\n\n* Urinary protein is > 1 + on dipstick and the required following 24-hour urine collection shows urinary protein > 2000 mg;\n* Serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation of study treatment;\n* History of gastrointestinal perforation and/or fistulae within 6 months prior to initiation of study treatment;\n* Presence of a bowel obstruction, history or presence of inflammatory enteropathy, or extensive intestinal resection, Crohn disease, ulcerative colitis, or chronic diarrhea;\n* Uncontrolled arterial hypertension >/= 150/ >/= 90 millimeter of mercury (mmHg) despite standard medical management;\n* Chronic therapy with non-steroidal anti-inflammatory agents or other anti-platelet agents.\n\nGastric Cancer Exclusion Criteria:\n\n* Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy;\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;\n* History of leptomeningeal disease;\n* Active or history of autoimmune disease or immune deficiency;\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan;\n* Positive test for human immunodeficiency virus (HIV) at screening;\n* Active hepatitis B virus (HBV) or hepatitis C (HCV) infection;\n* Severe infection within 4 weeks prior to initiation of study treatment;\n* Significant cardiovascular disease;\n* Significant bleeding disorder;\n* Prior allogeneic stem cell or solid organ transplantation;\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study;\n* Treatment with anticoagulation with warfarin, low-molecular-weight heparin, or similar agents for therapeutic purposes;\n* History of malignancy other than gastric or gastroesophageal junction carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death;\n* Known allergy or hypersensitivity to any of the study drugs or their excipients.\n\nEsophageal Cancer Cohort Exclusion Criteria:\n\n* High risk for developing esophageal fistula by clinical assessment or imaging;\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) Metastases;\n* Positive EBV viral capsid antigen IgM test at screening;\n* History of leptomeningeal disease;\n* Active or history of autoimmune disease or immune deficiency;\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan;\n* Active tuberculosis;\n* Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina;\n* History of malignancy other than esophageal cancer within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death;\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab or within 90 days after the final dose of tiragolumab.",
    "miscellaneous_criteria": ""
}